In summary, through data analysis, imaging and functional assays in in vitro and in vivo preclinical models, we demonstrated the anti-cancer effects and feasibility of selectively targeting BMP2/4 in SMAD4 negative EAC by novel anti BMP4 and BMP2/4 VHHs. The gene discussed is SMAD4; the disease is cancer.